Skip to content Skip to navigation

Selecta Biosciences, Inc.

Selecta Biosciences, Inc.

Selecta Biosciences is a clinical-stage biotechnology company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications with the potential for improved efficacy and safety profiles.

Fully synthetic vaccine manufacturing offers a number of compelling benefits, including flexible modular vaccine design and reduced development cost and time. While production and regulatory processes for biologically produced vaccines are often complex and time consuming, Selecta's SVP™ vaccines can be developed and approved faster for the following reasons:

* Self assembly technology enables SVP™ design variations that are analogous to structure–activity relation analyses used in small molecule drug discovery.
* Modular building blocks enable robust and rapid product development.
* Demonstrated scalability is based upon use of established pharmaceutical unit operations and processes.

Selecta's SVP™ platform technology enables diverse vaccine applications and designs. The company has created two distinct products: targeted Synthetic Vaccine Particles (tSVP™) and targeted tolerogenic Synthetic Vaccine Particles (t2SVP™).

Selecta Biosciences, Inc.
480 Arsenal St.
Building One
Watertown, MA
view on map